Download PDF
Semin Neurol 2005; 25(1): 64-68
DOI: 10.1055/s-2005-867075
Copyright © 2005 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Sleep Disorders in Multiple Sclerosis

W. Elon Fleming1 , Charles P. Pollak2
  • 1Sleep Disorders Center, Island Hospital, Anacortes, Washington
  • 2Sleep Laboratory, Cornell Medical Center, New York, New York
Further Information

Publication History

Publication Date:
29 March 2005 (online)

    Permissions and Reprints

ABSTRACT

Sleep disorders are pervasive in patients with multiple sclerosis (MS) although clinically underrecognized by most physicians. The most common sleep disorders seen in patients with MS include insomnia, nocturnal movement disorders, sleep-disordered breathing, narcolepsy, and rapid eye movement sleep behavior disorder. Factors that influence the quality of sleep in this patient population include pain, nocturia, depression, medication effect, location of lesions, and disease severity. Disrupted sleep has the potential to cause daytime somnolence, increased fatigue, and nonrefreshing sleep, and it may be associated with dangerous respiratory events. Awareness and treatment of these conditions is vital to improving health and quality of life in patients with MS.

KEYWORDS

Sleep disorders - multiple sclerosis - insomnia - narcolepsy

REFERENCES

  • 1 Tachibana N, Howard R S, Hirsch N P, Miller D H, Moseley I F, Fish D. Sleep problems in multiple sclerosis.  Eur Neurol. 1994;  34 320-323
    PubMedGoogle Scholar
  • 2 Saunders J, Whitham R, Schaumann B. Sleep disturbance, fatigue, and depression in multiple sclerosis.  Neurology. 1991;  41(suppl 1) 320
    PubMedGoogle Scholar
  • 3 Leo G J, Rao M, Bernardin L. Sleep disturbances in multiple sclerosis.  Neurology. 1991;  41(suppl 1) 320
    PubMedGoogle Scholar
  • 4 Achiron A, Barak Y, Gabbay U. Sleep disturbance in multiple sclerosis: clinical and neuroradiologic correlations related to disease activity.  J Neuroimmunol. 1995;  56-63(suppl 1) 57
    PubMedGoogle Scholar
  • 5 Ford D E, Kamerow D B. Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention?.  JAMA. 1989;  262 1479-1484
    CrossrefPubMedGoogle Scholar
  • 6 Sadovnick A D, Remick R A, Allen J et al.. Depression and multiple sclerosis.  Neurology. 1996;  46 628-632
    CrossrefPubMedGoogle Scholar
  • 7 Feinstein A, Kartsounis L D, Miller D H, Youl B D, Ron M A. Clinically isolated lesions of the type seen in multiple sclerosis: a cognitive, psychiatric, and MRI follow up study.  J Neurol Neurosurg Psychiatry. 1992;  55 869-876
    PubMedGoogle Scholar
  • 8 Fruehwald S, Loeffler-Stastka H, Eher R, Saletu B, Baumhackl U. Depression and quality of life in multiple sclerosis.  Acta Neurol Scand. 2001;  104 257-261
    CrossrefPubMedGoogle Scholar
  • 9 Rae-Grant A D, Eckert N J, Bartz S, Reed J F. Sensory symptoms of multiple sclerosis: a hidden reservoir of morbidity.  Mult Scler. 1999;  5 179-183
    CrossrefPubMedGoogle Scholar
  • 10 Ferini-Strambi L, Filippi M, Martinelli V et al.. Nocturnal sleep study in multiple sclerosis: correlations with clinical and brain magnetic resonance imaging findings.  J Neurol Sci. 1994;  125 194-197
    CrossrefPubMedGoogle Scholar
  • 11 Coleman R M, Pollak C P, Weitzman E D. Periodic movements in sleep (nocturnal myoclonus): relation to sleep disorders.  Ann Neurol. 1980;  8 416-421
    CrossrefPubMedGoogle Scholar
  • 12 Ekbom K A. Restless legs: a clinical study.  Acta Med Scand Suppl. 1945;  158 1
    PubMedGoogle Scholar
  • 13 Strang R R. The symptom of restless legs.  Med J Aust. 1967;  1 1211-1213
    PubMedGoogle Scholar
  • 14 Lavigne G J, Montplaisir J Y. Restless legs syndrome and sleep bruxism: prevalence and association among Canadians.  Sleep. 1994;  17 739-743
    PubMedGoogle Scholar
  • 15 Coleman R M, Bliwise D L, Sajben N et al.. Epidemiology of periodic limb movements during sleep. In: Guilleinault C, Lugaresi E Sleep/Wake Disorders: Natural History, Epidemiology and Long Term Evolution New York; Raven Press 1988: 217-229
    Google Scholar
  • 16 Montplaisir J, Boucher S, Poirier G, Lavigne G, Lapierre O, Lesperance P. Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria.  Mov Disord. 1997;  12 61-65
    CrossrefPubMedGoogle Scholar
  • 17 Montplaisir J, Lapierre O, Warnes H, Pelletier G. The treatment of the restless leg syndrome with or without periodic leg movements in sleep.  Sleep. 1992;  15 391-395
    PubMedGoogle Scholar
  • 18 Lugaresi E, Cirignotta F, Coccagna G, Montagna P. Nocturnal myoclonus and restless legs syndrome.  Adv Neurol. 1986;  43 295-307
    PubMedGoogle Scholar
  • 19 Desautels A, Turecki G, Montplaisir J, Sequeira A, Verner A, Rouleau G A. Identification of a major susceptibility locus for restless legs syndrome on chromosome 12q.  Am J Hum Genet. 2001;  69 1266-1270
    CrossrefPubMedGoogle Scholar
  • 20 Bonati M T, Ferini-Strambi L, Aridon P, Oldani A, Zucconi M, Casari G. Autosomal dominant restless legs syndrome maps on chromosome 14q.  Brain. 2003;  126 1485-1492
    CrossrefPubMedGoogle Scholar
  • 21 Onen S H, Alloui A, Gross A, Eschallier A, Dubray C. The effects of total sleep deprivation, selective sleep interruption and sleep recovery on pain tolerance thresholds in healthy subjects.  J Sleep Res. 2001;  10 35-42
    CrossrefPubMedGoogle Scholar
  • 22 Solaro C, Uccelli M M, Guglieri P, Uccelli A, Mancardi G L. Gabapentin is effective in treating nocturnal painful spasms in multiple sclerosis.  Mult Scler. 2000;  6 192-193
    CrossrefPubMedGoogle Scholar
  • 23 Amarenco G, Kerdraon J, Denys P. [Bladder and sphincter disorders in multiple sclerosis. Clinical, urodynamic and neurophysiological study of 225 cases].  Rev Neurol (Paris). 1995;  151 722-730
    PubMedGoogle Scholar
  • 24 Leo G J, Rao S M, Bernardin L. Sleep disturbance in multiple sclerosis.  Neurology. 1991;  41(suppl 1) 320 , (Abstract)
    PubMedGoogle Scholar
  • 25 Nuotio M, Tammela T L, Luukkaala T, Jylha M. Predictors of institutionalization in an older population during a 13-year period: the effect of urge incontinence.  J Gerontol A Biol Sci Med Sci. 2003;  58 756-762
    PubMedGoogle Scholar
  • 26 Valiquette G, Herbert J, Maede-D'Alisera P. Desmopressin in the management of nocturia in patients with multiple sclerosis. A double-blind, crossover trial.  Arch Neurol. 1996;  53 1270-1275
    PubMedGoogle Scholar
  • 27 Rebif®. Product information, 2002
  • 28 Huber S, Spycher M, Lechner-Scott J, Bellaiche Y, Steck A J, Kappos L. [Multiple sclerosis: therapy with recombinant beta-1b interferon: initial results with 30 multiple sclerosis patients in northwest Switzerland].  Schweiz Med Wochenschr. 1996;  126 1475-1481
    PubMedGoogle Scholar
  • 29 Antonijevic I A, Steiger A. Depression-like changes of the sleep-EEG during high dose corticosteroid treatment in patients with multiple sclerosis.  Psychoneuroendocrinology. 2003;  28 780-795
    CrossrefPubMedGoogle Scholar
  • 30 Patten S B, Fridhandler S, Beck C A, Metz L M. Depressive symptoms in a treated multiple sclerosis cohort.  Mult Scler. 2003;  9 616-620
    CrossrefPubMedGoogle Scholar
  • 31 Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults.  N Engl J Med. 1993;  328 1230-1235
    CrossrefPubMedGoogle Scholar
  • 32 Auer R N, Rowlands C G, Perry S F, Remmers J E. Multiple sclerosis with medullary plaques and fatal sleep apnea (Ondine's curse).  Clin Neuropathol. 1996;  15 101-105
    PubMedGoogle Scholar
  • 33 Wunderlin B W, Kesselring J, Ginzler H et al.. Fatigue in multiple sclerosis is not due to sleep apnea.  Eur J Neurol. 1997;  4 72-78
    PubMedGoogle Scholar
  • 34 Howard R S, Wiles C M, Hirsch N P, Loh L, Spencer G T, Newsom-Davis J. Respiratory involvement in multiple sclerosis.  Brain. 1992;  115 479-494
    PubMedGoogle Scholar
  • 35 Schrader H, Gotlibsen O B, Skomedal G N. Multiple sclerosis and narcolepsy/cataplexy in a monozygotic twin.  Neurology. 1980;  30 105-108
    PubMedGoogle Scholar
  • 36 Bonduelle M, Degos C. Symptomatic narcolepsies: a critical study. In: Guilleminault C, Dement WC, Passouant P Narcolepsy New York; Spectrum 1976: 322-325
    Google Scholar
  • 37 Langdon N, Welsh K I, van Dam M, Vaughan R W, Parkes D. Genetic markers in narcolepsy.  Lancet. 1984;  2 1178-1180
    PubMedGoogle Scholar
  • 38 Caballero A, Alves-Leon S, Papais-Alvarenga R, Fernandez O, Navarro G, Alonso A. DQB1*0602 confers genetic susceptibility to multiple sclerosis in Afro-Brazilians.  Tissue Antigens. 1999;  54 524-526
    CrossrefPubMedGoogle Scholar
  • 39 Mignot E, Lin X, Arrigoni J et al.. DQB1*0602 and DQA1*0102 (DQ1) are better markers than DR2 for narcolepsy in Caucasian and black Americans.  Sleep. 1994;  17(suppl 8) S60-S67
    PubMedGoogle Scholar
  • 40 Juji T, Satake M, Honda Y, Doi Y. HLA antigens in Japanese patients with narcolepsy. All the patients were DR2 positive.  Tissue Antigens. 1984;  24 316-319
    CrossrefPubMedGoogle Scholar
  • 41 Duquette P, Decary F, Pleines J et al.. Clinical sub-groups of multiple sclerosis in relation to HLA: DR alleles as possible markers of disease progression.  Can J Neurol Sci. 1985;  12 106-110
    PubMedGoogle Scholar
  • 42 Younger D S, Pedley T A, Thorpy M J. Multiple sclerosis and narcolepsy: possible similar genetic susceptibility.  Neurology. 1991;  41 447-448
    PubMedGoogle Scholar
  • 43 Iseki K, Mezaki T, Oka Y et al.. Hypersomnia in MS.  Neurology. 2002;  59 2006-2007
    PubMedGoogle Scholar
  • 44 Billiard M, Besset A, Montplaisir J et al.. Modafinil: a double-blind multicentric study.  Sleep. 1994;  17(suppl 8) S107-S112
    PubMedGoogle Scholar
  • 45 Kato T, Kanbayashi T, Yamamoto K et al.. Hypersomnia and low CSF hypocretin-1 (orexin-A) concentration in a patient with multiple sclerosis showing bilateral hypothalamic lesions.  Intern Med. 2003;  42 743-745
    CrossrefPubMedGoogle Scholar
  • 46 Rammohan K W, Rosenberg J H, Lynn D J, Blumenfeld A M, Pollak C P, Nagaraja H N. Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study.  J Neurol Neurosurg Psychiatry. 2002;  72 179-183
    CrossrefPubMedGoogle Scholar
  • 47 Scammell T E, Estabrooke I V, McCarthy M T et al.. Hypothalamic arousal regions are activated during modafinil-induced wakefulness.  J Neurosci. 2000;  20 8620-8628
    PubMedGoogle Scholar
  • 48 Tison F, Wenning G K, Quinn N P, Smith S J. REM sleep behaviour disorder as the presenting symptom of multiple system atrophy.  J Neurol Neurosurg Psychiatry. 1995;  58 379-380
    PubMedGoogle Scholar
  • 49 Uchiyama M, Isse K, Tanaka K et al.. Incidental Lewy body disease in a patient with REM sleep behavior disorder.  Neurology. 1995;  45 709-712
    CrossrefPubMedGoogle Scholar
  • 50 Wright B A, Rosen J R, Buysse D J, Reynolds C F, Zubenko G S. Shy-Drager syndrome presenting as a REM behavioral disorder.  J Geriatr Psychiatry Neurol. 1990;  3 110-113
    PubMedGoogle Scholar
  • 51 Plazzi G, Montagna P. Remitting REM sleep behavior disorder as the initial sign of multiple sclerosis.  Sleep Med. 2002;  3 437-439
    PubMedGoogle Scholar

W. Elon FlemingM.D. 

Medical Director, Sleep Disorders Center, Island Hospital

1211 24th Street, Anacortes, WA 98221